CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
News

Ubrogepant

Ubrogepant

In December 2019, Ubrelvy (ubrogepant) became the first oral CGRP receptor antagonist (gepant) to be approved for the acute treatment of migraine in adults. Approval was supported by data including the results of two Phase 3 clinical trials, ACHIEVE 1 and 2 of ubrogepant in the acute treatment of migraine.  A Phase 1 trial demonstrated the tolerability and safety of intermittent, high frequency dosing of ubrogepant.


Download slideset »


« back to Slides